Production of Therapeutic Proteins in Lower Eukaryotes

Information

  • Research Project
  • 6549759
  • ApplicationId
    6549759
  • Core Project Number
    R43GM066690
  • Full Project Number
    1R43GM066690-01
  • Serial Number
    66690
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/15/2002 - 22 years ago
  • Project End Date
    2/15/2003 - 22 years ago
  • Program Officer Name
    IKEDA, RICHARD A.
  • Budget Start Date
    8/15/2002 - 22 years ago
  • Budget End Date
    2/15/2003 - 22 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/15/2002 - 22 years ago
Organizations

Production of Therapeutic Proteins in Lower Eukaryotes

DESCRIPTION (provided by applicant): The pharmacological efficacy of a protein often depends on the protein's glycosylation structure, and successful manufacturing relies on host systems that produce glycoforms similar to those in humans. The overall objectives of this project are to develop tools for the metabolic engineering of fungal glycosylation pathways and to use these tools toward the creation of fungal strains capable of producing and secreting large quantities of recombinant therapeutic proteins with human-like glycosylation structures. The tool development strategy centers on a library-based approach that will allow rapid identification of properly targeted and expressed glycosylation enzymes in a high throughput manner. PROPOSED COMMERICIAL APPLICATIONS: The current method of glycoprotein production based on mammalian cell culture systems, specifically Chinese hamster ovary cell lines and mouse fibroblast/myeloma cell lines, presents manufacturers with the problems of low production levels, high cost, and safety. In its present state, protein production technology cannot keep up with research and development efforts, making manufacturing the growth-limiting factor for the biotechnology industry. With 84 biological drugs on the market and well over 500 in clinical development, the proposed project will generate technology toward the manufacturing of glycosylated proteins with high production levels in a safe and cost-effective manner, thereby alleviating the production bottleneck and allowing more products to reach the patients who need them.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GLYCOFI, INC.
  • Organization Department
  • Organization DUNS
    928700132
  • Organization City
    LEBANON
  • Organization State
    NH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    03766
  • Organization District
    UNITED STATES